Project Grant P50CA302572
- The University of Iowa received a $155,500 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant funding will support a targeted approach to inhibiting the NRF2 pathway in neuroendocrine cancers. This award, with a performance period from November 1, 2024 to October 31, 2026, is part of the program's efforts to transform healthcare for military service members and the general public...
- The University of Iowa was awarded a $1,354,009 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant, which runs from September 1, 2024 to August 31, 2027, aims to develop clinically deliverable RNA strategies for radiation protection. Specifically, the project will leverage the protective qualities of extremophile proteins and new delivery methods to reduce the impact of radiation-induced injuries...
- The Dana-Farber Cancer Institute, Inc. (DFCI) received a $2,452,400 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to conduct a program titled "Convergent Epigenetic Control of Diverse Neuroendocrine Cancers". The 5-year program, which began on April 1, 2025, aims to study the epigenetic and transcriptional states required for the development of neuroendocrine cancers across four tissue types: small intestinal...
- The University of Iowa was awarded a $777,500.00 Project Grant from the Defense Health Agency to conduct research under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2023, will fund a 3-year project to identify genetic mechanisms driving the transition of benign nevi to malignant melanoma. As a leading public research university, the University of Iowa has extensive experience delivering high-quality biomedical research, healthcare services,...
- The University of Iowa was awarded an $810,971 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The award will fund research from April 2021 through April 2024 to target a protumorigenic immunosuppressive loop in malignant peripheral nerve sheath tumors (MPNST). The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative solutions for...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $233,250.00 to support research at the University of Iowa targeting Delta-like ligand 3 with gamma delta T cell engagers to treat neuroendocrine prostate cancer. The project aims to develop innovative medical solutions to address critical health challenges relevant to military personnel and the broader public. The award period runs from November 1, 2025 to...
- The National Cancer Institute (NCI) awarded a $361,695 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Oklahoma Health Sciences Center (OUHSC) for the period of September 1, 2025 to August 31, 2029. The grant aims to: 1) Leverage novel mHealth applications to boost enrollment in NCI-sponsored clinical trials, 2) Promote representative clinical trial enrollment from the local catchment area population, 3) Expand Veteran access to NCI trials, and 4)...
- This $1,271,498 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division, aims to demonstrate the utility of a transgenic porcine (pig) model of pancreatic cancer for testing novel neoadjuvant therapies and evaluating endoscopic medical devices for imaging and treatment. The key objectives are: 1) to show that the porcine model can...
- The University of Iowa will receive $772,480 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research to delineate novel molecular pathways critical for the growth of GNAQ/11-mutant uveal melanoma cells. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through innovative...
- The National Cancer Institute awarded a $119,858 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The award supports research to elucidate mechanisms governing immune surveillance and resistance to antitumor T cell response in pancreatic cancer. The project aims to identify ways to safely promote T cell-mediated destruction of pancreatic cancer through combinatorial immunotherapies....
The University of Iowa received a $2,185,934 Project Grant award on August 28, 2025 from the National Cancer Institute (CFDA 93.397 - Cancer Centers Support Grants) to support its Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer. The grant will fund three key research projects over the 5-year period ending July 31, 2030: A multi-institutional investigation of a new strategy to sensitize pancreatic neuroendocrine tumors (PNETs) to immune checkpoint inhibitor therapy, culminating in a Phase 1b clinical trial. Pre-clinical studies on radiation-induced lipid peroxidation combined with a Phase 1 trial of alpha-emitter radiation therapy using 212Pb pentixather targeting C-X-C receptor 4 (CXCR4) in lung neuroendocrine tumors and carcinomas. An investigation of the tumor-promoting potential of GLP1 and GIP receptor agonists in gastroenteropancreatic neuroendocrine tumors. The grant will also support four interactive cores at the University of Iowa to facilitate collaboration, provide access to biospecimens, offer biostatistical support, and enable clinical data access and analysis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.2m | 8/27/25 |